



PATENT
Customer No. 22,852
Attorney Docket No. 09757.0007

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Maria PRAT QUINONES et al.

Application No.: 10/518,496

Filing Date: December 20, 2004

For: **NOVEL QUINUCLIDINE DERIVATIVES
AND MEDICINAL COMPOSITIONS
CONTAINING THE SAME**

)
)
) Group Art Unit: 1614
)
) Examiner: Unassigned
)
) Confirmation No.: 4930
)
)
)
)

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Box: PCT

Sir:

SECOND SUPPLEMENTAL INFORMATION DISCLOSURE
STATEMENT UNDER 37 C.F.R. § 1.97(b)

Pursuant to 37 C.F.R. §§ 1.56 and 1.97(b), applicants bring to the attention of the Examiner the documents on the attached listing. This Information Disclosure Statement is being filed before the mailing date of a first Office Action on the merits for the above-referenced application

Copies of the listed foreign and non-patent literature documents are attached. With respect to the enclosed non-English language document, Applicants submit the following remarks:

1. Konzett, H. and Rossler, R. (1940) "Versuchsanordnung zu Untersuchungen an der Brochialmuskulatur," Arch. Exp. Path. Pharmacol. 195: 71-74. This reference is discussed in the specification at p. 31, lines 24-25.

Applicants respectfully request that the Examiner consider the listed documents and indicate that they were considered by making appropriate notations on the attached form.


This submission does not represent that a search has been made or that no better art exists and does not constitute an admission that each or all of the listed documents are material or constitute "prior art." If the Examiner applies any of the documents as prior art against any claim in the application and applicants determine that the cited documents do not constitute "prior art" under United States law, applicants reserve the right to present to the office the relevant facts and law regarding the appropriate status of such documents.

Applicants further reserve the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents, should one or more of the documents be applied against the claims of the present application.

If there is any fee due in connection with the filing of this Statement, please charge the fee to our Deposit Account No. 06-0916.

Respectfully submitted,

FINNEGAN, HENDERSON, FARABOW,
GARRETT & DUNNER, L.L.P.

By: 
Carlos M. Tellez
Reg. No. 48,638

Dated: August 29, 2006

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet

1

of

2

Complete if Known

Application Number	10/518,496
Filing Date	December 20, 2004
First Named Inventor	Maria Prat Quinones
Art Unit	1614
Examiner Name	
Attorney Docket Number	09757.0007-00000

U.S. PATENTS AND PUBLISHED U.S. PATENT APPLICATIONS

Examiner Initials	Cite No.	Document Number	Issue or Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code (if known)			
	1	2,762,796	9/11/1956	Morel et al.	
	2	US-2004/0063950	4/1/2004	Farrerons Gallemi et al.	
	3	US-2004/0235887	11/25/2004	Farrerons Gallemi et al.	
	4	US-2004/0242629 A1	12/2/2004	Buil Albero et al.	
	5	US-2004/0266816 A1	12/30/2004	Buil Albero et al.	
	6	US-2005/0043349	2/24/2005	Catena Ruiz et al.	
	7	US-6,916,828 B2	7/12/2005	Farrerons Gallemi et al.	

FOREIGN PATENT DOCUMENTS

Examiner Initials	Cite No.	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	Translation
		Country Code Number Kind Code (if known)				
	8	GB 1 246 606	7/12/2005	Stargardzkie Zaklady		
	9	WO 03/053966 A2	7/3/2003	Laboratorios SALVAT, SA		
	10	WO 2004/000840	12/31/2003	Almirall Prodesfarma AG		
	11	WO 2004/005285	1/15/2004	Almirall Prodesfarma AG		
	12	WO 93/15080	8/5/1993	Smithkline Beecham		

NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Translation
	13	Abstract for Wallis, R.M. & Napier, C.M. Life Sci. 64(6-7):395-401 (1996) PMID 10069502.	
	14	Abstract for White, M.V. J. Allergy Clin. Immunol. 95(5 pt 2): 1065-68 (1995) PMID 7751523.	
	15	Brown, J.H. and Taylor, P. (2001) "Muscarinic Receptor Agonists and Antagonists," Chapter 7 in The Pharmacological Basis of Therapies. Goodman et al. eds., McGraw Hill: 10th edition, pp. 155-173.	
	16	Eglen, R.M. and Hedge, S.S. (1997) "Muscarinic Receptor Subtypes: Pharmacology and Therapeutic Potential," Drug News Perspect. 10(8): 462-469.	

Examiner
SignatureDate
Considered

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Complete if Known

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet

2

of

2

Application Number

10/518,496

Filing Date

December 20, 2004

First Named Inventor

Maria Prat Quinones

Art Unit

1614

Examiner Name

Attorney Docket Number

09757.0007-00000

NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Translation
	17	Eglen, R.M. et al. "Therapeutic opportunities from muscarinic receptor research," TRENDS in Pharm. Sci. 22(8), August 2001, 409-414.	
	18	Fryer et al., Am. J. Respir. Crit. Care Med. 158:S154-S160 (1998)	
	19	Interview Summary dated January 19, 2006, from US Application No. 10/404,395.	
	20	Interview Summary/Office Action dated February 28, 2005, from US Application No. 10/404,395.	
	21	Interview Summary/Office Action dated February 28, 2005, in U.S. Application No. 10/193,622.	
	22	Konzett, H. and Rossler, R. (1940). "Versuchsanordnung zu Untersuchungen an der Brochialmuskulatur," Arch. Exp. Path. Pharmacol. 195: 71-74.	
	23	Notice of Allowance/Notice of Allowability, dated January 19, 2006, from US Application No. 10/404,395	
	24	Office Action dated February 3, 2005, from US Application No. 10/404,395.	
	25	Office Action dated February 3, 2005, in U.S. Application No. 10/193,622.	
	26	Office Action dated May 18, 2005, from US Application No. 10/404,395.	
	27	Office Action dated May 18, 2005, in U.S. Application No. 10/193,622.	
	28	Office Action dated November 1, 2005, in U.S. Application No. 10/193,622.	
	29	Rang, H.P. et al. (1995). "Cholinergic Transmission," Chapter 6 in Pharmacology. Churchill Livingstone, New York, NY: 3rd Edition, pp. 117-147.	
	30	Ringdahl, R. et al. (1979). "Facile Preparation of the Enantiomers of 3-acetoxyquinuclidine and 3-quinuclidinol," Acta Pharm Suec. 16: 281-283.	
	31	Saraswati, M. et al. (1994). "Structure Activity Studies of N,N-Dialkyl and Cycloalkyl Carbamate Esters of Dimethylethanolamine and Choline with Nicotine and Muscarinic Cholinergic Properties," Drug Development Research 31: 142-146.	
	32	Shutske, G.M. (1990) "A Novel Synthesis of the Isoxazolo[5,4,3-k]-acridine Ring System," J. Heterocyclic Chem. 27: 1617-1621.	
	33	van Zwieten et al. Cardiovascular drugs and therapy/sponsored by the International Society of Cardiovascular Pharmacotherapy, 1995, 9(1): 159-67.	
	34	Waelbroeck, M. et al. (1990). "Binding of Selective Antagonists to Four Muscarinic Receptors (M1 to M4) in Rat Forebrain," Molecular Pharmacology. 38:267-273.	
	37	Xu et al. Chemical & Pharmaceutical Bulletin, 1998, 46(2): 231-241.	
	38	Notice of Allowance/Notice of Allowability, dated May 25, 2006, from US Application No. 10/193,622	
	39	Office Action dated July 13, 2006, from US Application No. 10/404,395.	

Examiner
SignatureDate
Considered

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.